Download PDF
Krankenhaushygiene up2date 2016; 11(02): 187-198
DOI: 10.1055/s-0042-108848
Nosokomiale Infektionen
© Georg Thieme Verlag KG Stuttgart · New York

Multiresistente Erreger – Therapiestrategien[*]

Christina Forstner
,
Mathias W. Pletz
Further Information

Publication History

Publication Date:
10 June 2016 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

  • Für schwere Infektionen durch MRSA stehen die Glykopeptide, Linezolid, Daptomycin und die 5. Generation-Cephalosporine zu Verfügung.

  • Bei leichten MRSA-Infektionen sind Cotrimoxazol und Doxycyclin orale Therapiealternativen.

  • Rifampicin ist ein möglicher Kombinationspartner bei Biofilm-assoziierten MRSA-Infektionen.

  • Rifampicin und Fosfomycin sollten wegen der schnellen Resistenzentwicklung nicht als Monotherapie eingesetzt werden.

  • Antibotika mit VRE-Wirksamkeit sind Linezolid, Daptomycin, Tigecyclin, Tedizolid und die neuen Lipoglykopeptide.

  • Tigecyclin hat ein breites Spektrum im grampositiven und gramnegativen Bereich, ist aber zur Monotherapie von schweren nosokomialen Infektionen, insbesondere bei Bakteriämie nicht geeignet.

  • Bei unkomplizierten Harnwegsinfektionen durch 3MRGN und 4MRGN sollen orale Carbapenem-sparende Substanzen (z. B. Nitrofurantoin oder Fosfomycin) eingesetzt werden, wenn sie empfindlich getestet sind.

  • Bei schweren Infektionen durch 3MRGN ist eine Monotherapie der noch wirksamen Antibiotikagruppe ausreichend, in der Regel eine Therapie mit einem Carbapenemen, u. U. auch Piperacillin-Tazobactam.

  • Eine neue Alternative bei Pyelonephritis und intraabdominellen Infektionen durch 3MRGN ist Ceftolozan/Tazobactam.

  • Bei schweren Infektionen durch 4MRGN, insbesondere KPC, scheint eine Kombinationstherapie (z. B. Dreifachkombination mit Colistin-Carbapenem-Tigecyclin oder Fosfomycin) vorteilhaft zu sein.

* Erstveröffentlichung in: Anästhesiol Notfallmed Schmerzther 2016; 51: 126 – 133


 

  • Literatur

  • 1 Carlet J, Jarlier V, Harbarth S et al. Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control 2012; 1: 11-11
    CrossrefGoogle Scholar
  • 2 World Health Organization. Antimicrobial resistance: global report on surveillance. 2014 http://www.apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
    Google Scholar
  • 3 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014
    Google Scholar
  • 4 Martin-Loeches I, Torres A, Rinaudo M et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 2015; 70: 213-222
    CrossrefGoogle Scholar
  • 5 Robert Koch-Institut. Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Empfehlungen der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) am Robert Koch Institut (RKI). Bundesgesundheitsbl 2012; 55: 1311-1354
    CrossrefGoogle Scholar
  • 6 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52
    Google Scholar
  • 7 Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 454-457
    CrossrefGoogle Scholar
  • 8 Forstner C, Dungl C, Tobudic S et al. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013; 19: 291-297
    CrossrefGoogle Scholar
  • 9 Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-629
    CrossrefGoogle Scholar
  • 10 Quinn DK, Stern TA. Linezolid and Serotonine Syndrome. Prim Care Companion. J Clin Psychiatry 2009; 11: 353-356
    Google Scholar
  • 11 Kalogeropoulos AS, Tsiodras S, Loverdos D et al. Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature. Med Case Rep 2011; 5: 13-13
    Google Scholar
  • 12 Harbarth S, van Dach E, Pagani L et al. Randomized non-inferiority trial to compare trimethoprim / sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 2015; 70: 264-272
    CrossrefGoogle Scholar
  • 13 Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;
    Google Scholar
  • 14 Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-1654
    CrossrefPubMedGoogle Scholar
  • 15 Jung YJ, Koh Y, Hong SB et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38: 175-180
    CrossrefGoogle Scholar
  • 16 Dalhoff K, Abele-Horn M, Andreas S et al. S3-Leitlinie: Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie. Pneumologie 2012; 66: 707-765
    Article in Thieme ConnectGoogle Scholar
  • 17 Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45: 2462-2472
    CrossrefGoogle Scholar
  • 18 Paterson DL. „Collateral Damage“ from Cephalosporin or Quinolone Antibiotic Therapy. Clin Infect Dis 2004; 38 (Suppl. 04) 341-345
    CrossrefGoogle Scholar
  • 19 Forstner C, Diab-Elschahawi M, Kivaranovic D et al. Non-linear significant relationship between use of glycopeptides and isolation of vancomycin-resistant Enterococcus species in a university hospital setting. Antimicrob Resist Infect Control 2015; 4: 25-25
    CrossrefGoogle Scholar
  • 20 O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015; 8: 217-230
    Google Scholar
  • 21 Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of inezolid versus Daptomycin for treatment of Vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58: 734-739
    CrossrefGoogle Scholar
  • 22 Britt NS, Potter EM, Patel N et al. Comparison of the effectiveness and safety of Linezolid and Daptomycin in Vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis 2015; 61: 871-878
    CrossrefGoogle Scholar
  • 23 Vardakas KZ, Tansarli GS, Rafailidis PI et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-2803
    CrossrefGoogle Scholar
  • 24 Leclercq R, Canto R, Brown DFJ et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013; 19: 141-160
    CrossrefGoogle Scholar
  • 25 Tamma PD, Han JH, Rock C et al. Carbapenem therapy is associated with improved survival compared with Piperacillin-Tazobactam for patients with extended-spectrum β-Lactamase Bacteremia. Clin Infect Dis 2015; 60: 1319-1325
    Google Scholar
  • 26 Rodriguez-Bano J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-174
    CrossrefGoogle Scholar
  • 27 Retamar P, Lopez-Cerero L, Muniain MA et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2013; 57: 3402-3404
    CrossrefGoogle Scholar
  • 28 Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist 2013; 6: 215-223
    Google Scholar
  • 29 Popejoy MW, Cloutier D, Huntington JA et al. Ceftolozane/tazobactam for the treatment of cUTI and cIAI caused by ESBL-producing Enterobacteriaceae. In: ID week 2014. Poster #260.
    Google Scholar
  • 30 Wagenlehner FM, Schmiermann G, Hoyrne U et al. Nationale S3-Leitlinie „Epidemiologie, Diagnostik, Therapie und Management unkomplizierter bakterieller ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten“ AWMF-Register-Nr. 043/044. im Internet: http//www.awmf.org
    Google Scholar
  • 31 Livermore DM, Warner M, Mushtaq S et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-419
    CrossrefGoogle Scholar
  • 32 Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant gram-negative bacteria. Expert Rev Anti Infect Ther 2013; 11: 1333-1353
    CrossrefPubMedGoogle Scholar
  • 33 Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-950
    CrossrefGoogle Scholar
  • 34 Galani I, Orlandou K, Moraitou H. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2014; 43: 370-374
    CrossrefGoogle Scholar
  • 35 Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections lowering mortality by antibiotics combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58: 2322-2328
    CrossrefGoogle Scholar
  • 36 Tumbarello M, De Pascale G, Trecarichi EM et al. Effect of aerolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144: 1768-1775
    CrossrefGoogle Scholar
  • 37 Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015; 43: 527-533
    CrossrefGoogle Scholar
  • 38 Zampieri FG, Nassar AP, Gusmao-Flores D et al. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care 2015; 19: 150-150
    CrossrefGoogle Scholar
  • 39 Livermore DM, Mushtaq S, Warner M et al. +Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-394
    CrossrefGoogle Scholar